Compare CENTA & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CENTA | SRPT |
|---|---|---|
| Founded | 1955 | 1980 |
| Country | United States | United States |
| Employees | 6000 | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | N/A | 2000 |
| Metric | CENTA | SRPT |
|---|---|---|
| Price | $38.45 | $15.68 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 4 | 29 |
| Target Price | ★ $36.75 | $25.85 |
| AVG Volume (30 Days) | 341.6K | ★ 3.6M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | N/A | ★ $2,198,237,000.00 |
| Revenue This Year | $1.60 | N/A |
| Revenue Next Year | $2.04 | N/A |
| P/E Ratio | $13.52 | ★ $5.51 |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $25.97 | $11.68 |
| 52 Week High | $39.99 | $25.32 |
| Indicator | CENTA | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 54.17 | 35.98 |
| Support Level | $36.52 | $15.55 |
| Resistance Level | $39.99 | $18.16 |
| Average True Range (ATR) | 1.30 | 0.93 |
| MACD | -0.10 | -0.35 |
| Stochastic Oscillator | 46.22 | 5.96 |
Central Garden & Pet Co offers solutions that support healthier pets, greener lawns, and thriving gardens. Its products include dog and cat treats, chews, toys, beds, containment, grooming supplies, aquatics, small animal and bird supplies, equine and livestock products, insect control solutions, grass seed, wild bird feed, fertilizers, pest controls, live plants, and packet seeds, sold under brands such as Aqueon, Nylabone, Kaytee, Farnam, Pennington, Ferry Morse, Amdro, and Sevin. The company operates through two segments, Pet and Garden, and sells through retailers, independent stores, eCommerce channels, and professional markets. It has sales and distribution operations mainly across the United States, with additional facilities in Canada and Mexico.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.